JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

Data ReadoutpositivebrepocitinibPositive

AI Analysis

Summary

Priovant Therapeutics announced publication of skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib in dermatomyositis in JAMA Dermatology, with previously reported positive efficacy and safety results including benefits on skin disease, muscle strength, and steroid-sparing.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 3 VALOR trial showed benefit on skin disease, muscle strength, physical function, and steroid-sparing measures in adults with dermatomyositis

Importance:7/10

Sentiment:

0.80

dermatologyJAK inhibitorTYK2publicationJAMA Dermatologymuscle disease

Related Companies

$INTI $SHWZ $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on August 26, 2026 3:11 PM

Read Original